ALT – altimmune, inc. (US:NASDAQ)

News

Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M [Yahoo! Finance]
Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap [Seeking Alpha]
Altimmune (ALT) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com